Covalon’s SurgiClear Dressing Plays an Important Part in Preventing Surgical Wound Infections at Top Children’s Hospital

A two-year study with the aim of preventing sternal wound infections highlights SurgiClear as a key component of the infection prevention bundle used to significantly reduce infection rates

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that its SurgiClear® dressing played a key part in an infection prevention bundle that significantly reduced surgical wound infections in a two-year quality improvement study recently published by Intermountain Primary Children’s Hospital, a not-for-profit children’s hospital associated with the University of Utah and part of the Intermountain Healthcare system.1 Intermountain Primary Children’s Hospital is recognized as one of the top children’s hospitals in the United States.

Describing the impact of the bundled intervention, published in The Annals of Thoracic Surgery, the authors from Intermountain Healthcare report that the annual rate of total surgical wound infections decreased from 2.83% in 2019 to 1.15% in 2021. The bundled approach used to improve perioperative infection prevention practices included implementation of SurgiClear as a main practice change.

Jeremy Harman, PA-C, an author of the study, commented, “The trifecta of breathable barrier protection, antimicrobials, and the ability to monitor the site is what makes this a great dressing. It’s easier for us to assess the wound and is more comfortable for patients.”

The aim of the project was to reduce the rate of surgical wound infections to less than 1.5% in pediatric cardiothoracic surgery patients. Surgical wound infections are a common complication of cardiac surgery, associated with increased length of hospital stay, readmissions, higher cost of care and increased mortality. Pediatric cardiology centers across the U.S. focusing on process improvement are investing in preventative strategies and quality improvement protocols to decrease the risk of surgical site infections. Advanced technology, such as Covalon’s SurgiClear, can help to standardize post-operative wound care.

“It is great to see another institution sharing their experience with our SurgiClear dressing through publication,” said Brian Pedlar, CEO. “At Covalon we’re committed to providing better experiences for patients and clinicians, and this work completed by Intermountain Primary Children’s Hospital shows how the best practices and products come together to do just that, helping the most vulnerable heal.”

SurgiClear is a dual-antimicrobial clear silicone surgical dressing that provides full site visibility, allowing for inspection of surgical wound sites, while minimizing contact and repetitive dressing removal. Its dual-antimicrobial silicone technology allows for broad spectrum protection from both gram-positive and gram-negative bacteria that is gentle on even the most sensitive skin.

In addition to SurigClear, Covalon’s other infection prevention solutions include:

  • VALGuard® – an FDA listed, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal.
  • IV Clear® – an antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It uses a soft silicone adhesive to preserve the skin’s barrier function and minimize skin injuries and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.

Reference

  1. Glenn, E. T., Harman, J. R., Marietta, J., Lake, J., Bailly, D. K., Ou, Z., Griffiths, E. R., & Ware, A. L. (2022). Impact of a Surgical Wound Infection Prevention Bundle in Pediatric Cardiothoracic Surgery. The Annals of Thoracic Surgery. https://doi.org/10.1016/j.athoracsur.2022.08.045

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version